Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00544
|
|||||
| Drug Name |
Cephradine
|
|||||
| Synonyms |
(6R,7R)-7-((R)-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(D-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-caboxylic acid; 7-(D-2-Amino-2-(1,4-cyclohexadienyl)acetamide)desacetoxycephalosporanicacid; 7beta-[(2R)-2-(cyclohexa-1,4-dienyl)-2-phenylacetamido]-3-methyl-3,4-didehydrocepham-4-carboxylic acid; Anspor; Anspor (TN); CEPHRADINE SODIUM; Cefradin; Cefradina; Cefradina [INN-Spanish]; Cefradine (JAN/INN); Cefradinum; Cefradinum [INN-Latin]; Cephradin; Cephradine; Cephradine (USP); Cephradine (anhydrous); Cephradine [USAN:BAN]; Eskacef; SK&F D-39304; SK-D-39304; SKF D 39304; SQ 11436; SQ-11436; SQ-22022; Sefril; VELOSEF 125; VELOSEF 250; VELOSEF 500; Velosef; Velosef (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Streptococcus pneumoniae infections [ICD11:CA40.0Y] | Approved | [1] | |||
| Therapeutic Class |
Antibiotics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C16H19N3O4S
|
|||||
| Canonical SMILES |
CC1=C(N2C(C(C2=O)NC(=O)C(C3=CCC=CC3)N)SC1)C(=O)O
|
|||||
| InChI |
InChI=1S/C16H19N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1
|
|||||
| InChIKey |
RDLPVSKMFDYCOR-UEKVPHQBSA-N
|
|||||
| CAS Number |
CAS 38821-53-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 349.4 | Topological Polar Surface Area | 138 | ||
| Heavy Atom Count | 24 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
0.4
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103590704
,104133787
,104328337
,11335914
,11361153
,11462125
,117600507
,124766238
,124894242
,126625602
,126656737
,134222860
,134337749
,135001466
,136212369
,136367999
,137006375
,137263524
,140396423
,144115808
,144207037
,15076177
,152100549
,160849687
,160964630
,162175008
,164788183
,170465355
,172914782
,174006223
,175442153
,175607974
,178101532
,179116612
,24278342
,34679326
,46505082
,47365212
,48415745
,49836646
,50050883
,50880148
,57312171
,7847330
,7978895
,8149240
,8175363
,9114
,92712397
,99301827
|
|||||
| ChEBI ID |
ChEBI:3547
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [2] | |
| PEPT2 | Transporter Info | Peptide transporter 2 | Substrate | [3] | ||
| References | ||||||
| 1 | Cephradine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997 Nov;273(5 Pt 2):F706-11. | |||||
| 3 | Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.